2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
10 October 2019SV NewsDDF hosts Second Annual Forum to review progress in novel dementia therapeutics
8 October 2019Portfolio NewsAVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
1 October 2019Portfolio NewsEndotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution
30 September 2019Portfolio NewsDDF notes Ribometrix strategic collaboration with Vertex Pharmaceuticals to discover and develop RNA-targeted small molecule therapeutics
27 September 2019Portfolio NewsMisonix, Inc. Completes Acquisition of Regenerative Medical Company Solsys Medical- 27 September 2019Portfolio NewsDDF notes Ribometrix raises $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform with Investment from DDF
24 September 2019Portfolio NewsArtios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States- 9 September 2019SV NewsDDF notes the appointment of Christian Jung, PhD as Partner
- 27 August 2019Portfolio NewsPIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
- 13 August 2019Portfolio NewsDeciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
12 August 2019Portfolio NewsDDF notes AstronauTx secures £6.5 million Financing with Investment from DDF
8 August 2019Portfolio NewsLilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia
